Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Core Viewpoint - Nuvectis Pharma, Inc. is advancing its clinical-stage drug candidate NXP900, a novel YES1/SRC kinase inhibitor, with upcoming presentations at the 2025 American Association for Cancer Research Meeting, highlighting its potential in treating advanced solid tumors and overcoming drug resistance in non-small cell lung cancer (NSCLC) [1][2]. Group 1: NXP900 Development - NXP900 is currently in a Phase 1a dose escalation study, demonstrating potent single-agent activity and synergy with ALK inhibitors in ALK-resistant NSCLC models [2][4]. - The drug targets YAP1 signaling in NSCLC cell lines and shows sensitivity in endocrine therapy-resistant luminal A breast cancer cell lines [2][4]. Group 2: Presentation Details - Nuvectis will present findings related to NXP900 in various sessions at the 2025 AACR Meeting, including "First-in-Human Phase I Clinical Trials" and "Drug Resistance in Molecular Targeted Therapies," scheduled for April 29th [3]. - Specific presentation times include sessions from 9:00 AM to 12:00 PM and 2:00 PM to 5:00 PM on the same day [3]. Group 3: Company Overview - Nuvectis Pharma, Inc. focuses on developing innovative precision medicines for serious unmet medical needs in oncology, with two clinical-stage candidates: NXP800 and NXP900 [4]. - NXP800 is an oral small molecule GCN2 activator in trials for platinum-resistant ovarian carcinoma and cholangiocarcinoma, while NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases [4].